about
Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoesSubsisting H1N1 influenza memory responses are insufficient to protect from pandemic H1N1 influenza challenge in C57BL/6 mice.Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques.Isospora troglodytes n. sp. (Apicomplexa: Eimeriidae), a new coccidian species from wrens of Costa Rica.Drug analog inhibition of indoleamine 2,3-dioxygenase (IDO) activity modifies pattern recognition receptor expression and proinflammatory cytokine responses early during influenza virus infection.Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.Interferon Lambda Upregulates IDO1 Expression in Respiratory Epithelial Cells After Influenza Virus Infection.Chikungunya viral arthritis in the United States: a mimic of seronegative rheumatoid arthritisBroadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress.Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis.Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infectionPathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence.Indoleamine 2,3-dioxygenase (IDO) activity during the primary immune response to influenza infection modifies the memory T cell response to influenza challenge.MUTATIONS IN THE E2 GLYCOPROTEIN AND THE 3' UNTRANSLATED REGION ENHANCE CHIKUNGUNYA VIRUS VIRULENCE IN MICE.Immune-Mediated Protection and Pathogenesis of Chikungunya Virus.Modified mRNA Vaccines Protect against Zika Virus Infection.Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice.Modified mRNA Vaccines Protect against Zika Virus Infection.Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complementOptimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytesA lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infectionHuman monoclonal antibodies against Ross River virus target epitopes within the E2 protein and protect against disease
P50
Q24701786-EF271AB6-E33D-4587-A346-4AAD19848812Q30429302-36BC2B12-6316-4984-90FB-5BBA65BB7701Q33853893-5B7A6D85-95EC-4252-BCD1-CB7CF722273AQ34050092-40F3B9AE-1FEA-4E5F-AC1E-7DB6D3DFC7CAQ34066721-8791F126-4B5C-4CD9-8A38-B1B39E02CAC8Q35850197-1D896526-93B4-438D-9885-F97EC7F2A6E1Q35865362-37E7BD82-5D3F-4652-A3C2-243412259370Q36114846-9BEC4644-5608-4262-8E6D-54600C8370E0Q36318652-5707EFDE-EA3A-4403-87CF-CE973BF71649Q36483436-59ABEBAB-99EF-45CE-AF1F-FF54E38E47E5Q37006795-644410B9-4DF9-4E4C-A093-BC16933405B9Q37214518-F1B32CE8-6939-4DD8-A321-BE900DC7B8B4Q37715931-65030BB4-630F-4825-91D1-66CD9402C6D4Q38659305-17D8DCA1-06DC-45BC-84BC-45078143CA2BQ39013750-B23567A3-D6F9-4E29-A5C4-2DCA4CA7870FQ40049416-2395197F-6A1C-426E-B847-81906497DEDBQ40052932-7BF87993-8546-4A82-B542-6986614427BAQ41981700-A7E5FA51-F2D4-475B-9BE7-4627639EDD84Q91011145-2618DFA5-D7D4-46D0-A1AA-9C05787AB560Q91842996-674B3A08-C02D-4626-8397-03BEEA1B2729Q92124331-B5BFA7A1-0A4B-4741-8855-F727C4086224Q94512392-0FDE7172-A9B4-4D0E-89F7-F5D6AD94C24B
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Julie M. Fox
@ast
Julie M. Fox
@en
Julie M. Fox
@es
Julie M. Fox
@nl
Julie M. Fox
@sl
type
label
Julie M. Fox
@ast
Julie M. Fox
@en
Julie M. Fox
@es
Julie M. Fox
@nl
Julie M. Fox
@sl
prefLabel
Julie M. Fox
@ast
Julie M. Fox
@en
Julie M. Fox
@es
Julie M. Fox
@nl
Julie M. Fox
@sl
P106
P1153
56829924600
P21
P31
P496
0000-0003-0567-738X